• NovaBridge Biosciences EVP, Clinical Development Xu Cong Claire reported an increase in ordinary share holdings tied to RSU vesting on Aug. 30.
• The filing shows 9,382 ordinary shares acquired via vesting, lifting direct holdings to 307,483 ordinary shares.
• She also sold 3,282 ordinary shares on Aug. 31 at USD 0.79 per share, reducing holdings to 304,201.
• RSU holdings rose to 28,558 following the Aug. 30 transaction.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NovaBridge Biosciences published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0002114309-26-000007), on September 01, 2026, and is solely responsible for the information contained therein.